🔗 Visit the ClinicalTrials.gov page for NCT00304954
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Immunology of age-related macular degeneration. | Nat Rev Immunol | 2013 | 2.14 |
| 2 | Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. | Nat Rev Drug Discov | 2012 | 1.52 |
| 3 | Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. | Arthritis Rheum | 2002 | 1.46 |
| 4 | The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. | Eye (Lond) | 2010 | 1.29 |
| 5 | IL-4 potentiates IL-1beta- and TNF-alpha-stimulated IL-8 and MCP-1 protein production in human retinal pigment epithelial cells. | Curr Eye Res | 1999 | 0.95 |
| 6 | Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. | Swiss Med Wkly | 2002 | 0.92 |
| 7 | Present and possible therapies for age-related macular degeneration. | ISRN Ophthalmol | 2014 | 0.79 |